Compare · ABT vs ONC
ABT vs ONC
Side-by-side comparison of Abbott Laboratories (ABT) and BeOne Medicines Ltd. (ONC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and ONC operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $157.63B, about 5.2x ONC ($30.11B).
- Over the past year, ABT is down 32.2% and ONC is up 2.7% - ONC leads by 34.9 points.
- ONC has been more active in the news (10 items in the past 4 weeks vs 6 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 6 for ONC).
- Company
- Abbott Laboratories
- BeOne Medicines Ltd.
- Price
- $90.44-0.69%
- $270.74+0.26%
- Market cap
- $157.63B
- $30.11B
- 1M return
- +4.00%
- -14.68%
- 1Y return
- -32.20%
- +2.68%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 6
- 10
- Recent ratings
- 25
- 6
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
- Director Conroy Kevin T was granted 2,286 units of Common shares without par value, increasing direct ownership by 2% to 133,737 units (SEC Form 4)
Latest ONC
- SEC Form 144 filed by BeOne Medicines Ltd.
- Director Yi Qingqing sold $65,596 worth of American Depositary Shares (235 units at $279.13), closing all direct ownership in the company (SEC Form 4) (for withholding tax)
- BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026
- BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026
- Director Riva Alessandro sold $65,617 worth of American Depositary Shares (212 units at $309.51), closing all direct ownership in the company (SEC Form 4) (tax liability)
- Director Dugan Margaret sold $65,636 worth of American Depositary Shares (212 units at $309.60), closing all direct ownership in the company (SEC Form 4) to cover taxes
- Director Sanders Corazon (Corsee) D. sold $65,633 worth of American Depositary Shares (212 units at $309.59), closing all direct ownership in the company (SEC Form 4) to cover taxes
- BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026
- Director Baker Bros. Advisors Lp sold $261,981 worth of Ordinary Shares (10,998 units at $23.82) (SEC Form 4) to satisfy withholding tax
- BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference